High Affinity Peptide Inhibitors of the Hepatitis C Virus NS3-4A Protease Refractory to Common Resistant Mutants

Protein transduction domain delivery of therapeutic macromolecules

(2011) Arjen van den Berg et al.   CURRENT OPINION IN BIOTECHNOLOGY

Hepatitis C virus resistance to protease inhibitors

(2011) Philippe Halfon et al.   JOURNAL OF HEPATOLOGY

A New Era of Hepatitis C Therapy Begins

(2011) Donald M. Jensen   NEW ENGLAND JOURNAL OF MEDICINE

XDS

(2010) Wolfgang Kabsch   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding

(2010) K. P. Romano et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Optimization of the multiple enzymatic activities of the hepatitis C virus NS3 protein

(2009) Shawn Misialek et al.   ANALYTICAL BIOCHEMISTRY

The efficacy and safety of telaprevir – a new protease inhibitor against hepatitis C virus

(2009) Ivan Gentile et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection

(2009) Christoph Sarrazin et al.   GASTROENTEROLOGY

New developments in the antiviral treatment of hepatitis C

(2009) J. de Bruijne et al.   VOX SANGUINIS

Challenges in Modern Drug Discovery: A Case Study of Boceprevir, an HCV Protease Inhibitor for the Treatment of Hepatitis C Virus Infection

(2008) F. George Njoroge et al.   ACCOUNTS OF CHEMICAL RESEARCH

Hepatitis C virus drug resistance and immune-driven adaptations: Relevance to new antiviral therapy

(2008) Silvana Gaudieri et al.   HEPATOLOGY